PURPOSE: To evaluate the relationship between treatment failure and COX-2 expression in nasopharyngeal cancer patients treated with chemotherapy and radiotherapy. MATERIALS AND METHODS: The subjects of this study were 22 nasopharyngeal cancer patients. The patients were treated with neoadjuvant chemotherapy, followed by radiotherapy, or with radiotherapy alone. The formalin-fixed, paraffin-embedded tissues of 11 patients who developed a locoregional recurrence (n=7) or distant metastasis (n=4) were compared with those of 11 disease free patients. Prognostic factors, including histological type, stage, radiation dose and chemotherapy, were well balanced between the two groups. The COX-2 expression was determined immunohistochemically. RESULTS: COX-2 expression was stronger in the patients with a locoregional recurrence or distant metastasis than in those free of disease. The COX-2 distribution scores of the control group were as follows: 0 in 7, 1 in 2 and 2 in 2 patients. In the recurrence group, the scores were as follows; 0 in 3, 1 in 1, 2 in 2 and 3 in 5 patients. COX-2 expression was shown to have a statistically significant influence on the treatment failure by the Mann-Whitney U test (p=0.024) and Mantel-Haenszel Chi-Square test (p=0.018). It also significantly influenced the treatment failure when an analysis was performed within patients with a undifferentiated histology (p=0.039 by the Mann-Whitney U test, p=0.037 by the Mantel-Haenszel Chi-Square test). CONCLUSION: COX-2 expression is believed to be one of the important factors associated with a locoregional recurrence or distant metastasis.
PURPOSE: To evaluate the relationship between treatment failure and COX-2 expression in nasopharyngeal cancerpatients treated with chemotherapy and radiotherapy. MATERIALS AND METHODS: The subjects of this study were 22 nasopharyngeal cancerpatients. The patients were treated with neoadjuvant chemotherapy, followed by radiotherapy, or with radiotherapy alone. The formalin-fixed, paraffin-embedded tissues of 11 patients who developed a locoregional recurrence (n=7) or distant metastasis (n=4) were compared with those of 11 disease free patients. Prognostic factors, including histological type, stage, radiation dose and chemotherapy, were well balanced between the two groups. The COX-2 expression was determined immunohistochemically. RESULTS:COX-2 expression was stronger in the patients with a locoregional recurrence or distant metastasis than in those free of disease. The COX-2 distribution scores of the control group were as follows: 0 in 7, 1 in 2 and 2 in 2 patients. In the recurrence group, the scores were as follows; 0 in 3, 1 in 1, 2 in 2 and 3 in 5 patients. COX-2 expression was shown to have a statistically significant influence on the treatment failure by the Mann-Whitney U test (p=0.024) and Mantel-Haenszel Chi-Square test (p=0.018). It also significantly influenced the treatment failure when an analysis was performed within patients with a undifferentiated histology (p=0.039 by the Mann-Whitney U test, p=0.037 by the Mantel-Haenszel Chi-Square test). CONCLUSION:COX-2 expression is believed to be one of the important factors associated with a locoregional recurrence or distant metastasis.
Authors: M Al-Sarraf; M LeBlanc; P G Giri; K K Fu; J Cooper; T Vuong; A A Forastiere; G Adams; W A Sakr; D E Schuller; J F Ensley Journal: J Clin Oncol Date: 1998-04 Impact factor: 44.544
Authors: K Kishi; S Petersen; C Petersen; N Hunter; K Mason; J L Masferrer; P J Tofilon; L Milas Journal: Cancer Res Date: 2000-03-01 Impact factor: 12.701
Authors: G Chan; J O Boyle; E K Yang; F Zhang; P G Sacks; J P Shah; D Edelstein; R A Soslow; A T Koki; B M Woerner; J L Masferrer; A J Dannenberg Journal: Cancer Res Date: 1999-03-01 Impact factor: 12.701
Authors: H Y Lim; H J Joo; J H Choi; J W Yi; M S Yang; D Y Cho; H S Kim; D K Nam; K B Lee; H C Kim Journal: Clin Cancer Res Date: 2000-02 Impact factor: 12.531
Authors: M Oshima; J E Dinchuk; S L Kargman; H Oshima; B Hancock; E Kwong; J M Trzaskos; J F Evans; M M Taketo Journal: Cell Date: 1996-11-29 Impact factor: 41.582
Authors: K M Sheehan; K Sheahan; D P O'Donoghue; F MacSweeney; R M Conroy; D J Fitzgerald; F E Murray Journal: JAMA Date: 1999-10-06 Impact factor: 56.272
Authors: E Giovannucci; K M Egan; D J Hunter; M J Stampfer; G A Colditz; W C Willett; F E Speizer Journal: N Engl J Med Date: 1995-09-07 Impact factor: 91.245